• Profile
Close

A prospective 5-year follow-up study after limited resection for lung cancer with ground-glass opacity

European Journal of Cardio-Thoracic Surgery Dec 14, 2017

Sagawa M, et al. - A prospective multi-institutional study evaluating the validity of limited resection for small-sized pulmonary adenocarcinoma with ground-glass opacity (GGO) was conducted. Researchers performed limited resection safely without any recurrence with the criteria of this study. Here, the postoperative pulmonary function was well preserved. For small-sized lung cancer with GGOs that met the criteria of this study, the outcomes of limited resection were satisfactory.

Methods

  • For this study, the inclusion criteria were 25–80 years of age, no prior treatment, a maximum tumour diameter of 8–20 mm, a GGO ratio of ≥ 80%, clinical T1N0M0, lower 18F-fluorodeoxyglucose accumulation than the mediastinum, resectable by sublobar resection, pulmonary lobectomy tolerable and an intraoperative pathological diagnosis of bronchiloalveolar carcinoma.
  • Researchers preferred wedge resection, but permitted segmentectomy.
  • Disease-specific survival and overall survival were analyzed.

Results

  • From 13 institutions, 73 patients were enrolled from November 2006 to April 2012.
  • Researchers identified that 1 patient was ineligible, and the remaining 72 patients were preregistered.
  • Intraoperatively, the tumours of 3 patients were diagnosed as benign lesions and 14 patients as adenocarcinomas with mixed subtype.
  • In 2 patients, intraoperative cytological/histological examination of surgical margin was not performed, and ultimately, the remaining 53 patients were eligible for this study.
  • They noticed the mean tumour size of 14.0 mm and the mean GGO ratio of 95.9%.
  • Wedge resection and segmentectomy were performed on 39 and 14 patients, respectively.
  • Despite intraoperative diagnosis of bronchioloalveolar carcinomas of all tumours, 6 were ultimately diagnosed as adenocarcinoma with a mixed subtype.
  • They performed no completion lobectomy.
  • As of 1 May 2017, they recognized no recurrence of the original lung cancer during 60.0–126.3 months after surgery.
  • Death of 2 patients from other diseases was noticed.
  • They noticed the 5-year disease-specific and overall survival rates of 100% and 98.1%, respectively.
  • Minimal reduction in the pulmonary function was evident after limited resection.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay